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TARGETING TRAF6 FOR CANCER THERAPEUTICAL DEVELOPMENT
John Kenneth Morrow, B.S.
Advisor: Shuxing Zhang, Ph.D.
Tumor necrosis factor (TNF)-Receptor Associated Factors (TRAFs) are a
family of signal transducer proteins. TRAF6 is a unique member of this family in
that it is involved in not only the TNF superfamily, but the toll-like receptor
(TLR)/IL-1R (TIR) superfamily. The formation of the complex consisting of
Receptor Activator of Nuclear Factor κ B (RANK), with its ligand (RANKL)
results in the recruitment of TRAF6, which activates NF-κB, JNK and MAP
kinase pathways. TRAF6 is critical in signaling with leading to release of various
growth factors in bone, and promotes osteoclastogenesis. TRAF6 has also been
implicated as an oncogene in lung cancer and as a target in multiple myeloma. In
the hopes of developing small molecule inhibitors of the TRAF6-RANK
interaction, multiple steps were carried out. Computational prediction of hot spot
residues on the protein-protein interaction of TRAF6 and RANK were examined.
Three methods were used: Robetta, KFC2, and HotPoint, each of which uses a
different methodology to determine if a residue is a hot spot. These hot spot
predictions were considered the basis for resolving the binding site for in silico
high-throughput screening using GOLD and the MyriaScreen database of
drug/lead-like compounds. Computationally intensive molecular dynamics
simulations highlighted the binding mechanism and TRAF6 structural changes
upon hit binding. Compounds identified as hits were verified using a GST-pull
down assay, comparing inhibition to a RANK decoy peptide. Since many drugs
v

fail due to lack of efficacy and toxicity, predictive models for the evaluation of
the LD50 and bioavailability of our TRAF6 hits, and these models can be used
towards other drugs and small molecule therapeutics as well. Datasets of
compounds and their corresponding bioavailability and LD50 values were curated
based, and QSAR models were built using molecular descriptors of these
compounds using the k-nearest neighbor (k-NN) method, and quality of these
models were cross-validated.
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Introduction:
TNF-Receptors Associated Factors (TRAFs) are a family of adapter proteins,
originally identified in humans and rodents by their association to the cytoplasmic tails of
different members of the TNF-Receptor (TNFR) family [1]. In mammals, TRAFs
contribute to the regulation of as many as 20 TNFRs [2-5]. TRAFs are primarily involved
in the signals regulating the inflammatory and immune systems, as well as regulating
apoptosis. There are seven members (TRAF1 through TRAF7) of the TRAF family, and
all but TRAF7 are characterized by a conserved, 180 residue fold called the TRAF
domain (TD). It is the TD that supports the interaction with TNFRs and other adapter
proteins; as one would expect, TRAF7 does not directly interact with TNFRs [3, 6]. The
TRAF domain has an α-helix segment followed by eight anti-parallel β-strands (also
called the TRAF-C domain) which fold into a β-sandwich structure, and usually
oligomerizes as mushroom-shaped trimers that are stabilized by the coiled-coil
interactions between the α-helices of each TD monomer [2, 6, 7]. As for the other
structural features in TRAFs, all contain one to seven zinc finger domains [8] and all but
TRAF1 have N-terminal RING-finger (Really Interesting New Gene) domain. All
mammalian TRAFs localize to the cytoplasm except TRAF4 which is found in the
nucleus.
Among the TRAF family members, TRAF6 has distinct features and
physiological functions that are not shared in other TRAFs. TRAF6 was first identified
by a yeast two-hybrid screen using the cytoplasmic tail of CD40 as bait and
independently by expressed sequence tag (EST) screening [9, 10]. Protein sequence and
phylogenetic studies revealed that is the older and less conserved TRAF family member
despite maintaining all of the structural characteristics of the other members of the
1

family. TRAF6 shares the smallest amount of homology to the prototypical TRAF
domain, and has the most divergent TRAF-C domain [11]. The unique function of
TRAF6 is primarily determined by its TRAF-C domain, which does not share the same
peptide motif interactions as TRAF1, -2, -3 or -5 [12-14]. TRAF6 binds to a consensus
sequence of: xxPxExx(Ac/Ar) (where the last residue is aromatic or acidic), whereas
TRAF1, -2, -3, or -5 bind to a (P/S/A/T)x(Q/E)E motif [2, 8, 15-17]. Another
distinguishing feature of TRAF6 from other TRAFs is its ability to transduce signals
from the TLR/IL-1R superfamily as well as the TNFR superfamily [18]. TRAF6 does not
have direct interaction with members of the TLR/IL-1R family. Instead, recruitment of
adaptors occur upon its activation, such as the myeloid differentiation factors 88
(MyD88), toll/interleukin-1 receptor adaptor protein (TIRAP), and TRIF-related adaptor
molecule (TRAM) [1]. Since TRAF6 is a central hub for a wide variety of signals, it is
not surprising that it can regulate an array of physiologic processes, including adaptive
and innate immunity, bone metabolism, and the development of structures such as
mammary glands, central nervous system, and the skin.
TRAF6 has an N-terminal RING-finger domain, followed by four zinc-finger
domains, the coiled-coil domain, and finally the C-terminal TRAF domain (Figure 1).
Again, this TD is comprised of eight anti-parallel β-strands that form a stable sandwich
structure, and are preceded by a single α-helix segment. The unique sequence specificity
of TRAF6 does not overlap with other TRAF members; it interacts directly with a subset
of the TNFR superfamily, two such examples of which are CD40 and Receptor activator
of nuclear factor-kappa B (RANK, also known as TRANCE-R).
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Figure 1. Domains of the TRAF6 protein.
The TRAF6 Protein consists of four parts: a Really Interesting New Gene (RING)
finger domain, four zinc finger (Zn finger) domains, a coiled-coil domain, and a Cterminal TRAF-C domain. The RING domain acts as an E3 ubiquitin ligase.
In addition to the signal transduction of the TNFR superfamily, TRAF6 is also a
significant transducer for the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR)
superfamily. Within the IL-1Rs and TLRs resides a component called the TIR domain; it
is this domain that recruits a family of TIR-domain containing signaling proteins,
including MyD88, Mal/TIRAP, TRIF, and TRAM [19]. As a result, these signaling
complexes recruit Serine/Threonine kinases in the IRAK family (IRAK1, IRAK2, IRAKM and IRAK4), which then interact with TRAF6 to activate downstream signal
transduction [20-23].
While TRAF6 mediates signaling in a wide spectrum of cellular physiological
functions, the interaction of TRAF6 and RANK are of special interest. The pair of RANK
and RANK ligand (RANKL) is essential for bone remodeling by regulation of osteoclasts
development and function [24] , mammary gland development [25] and lymph node
organogenesis [26, 27]. Also worthy of mention is the fact that the RANK/RANKL pair
controls the incidence and onset of progestin-driven breast cancer [28], and plays a
significant part in migration and metastatic behavior of cancer cells, acting as a fertile
3

soil for metastatic tumors going to the bone [29]. When the RANK/RANKL complex is
formed, TRAF6 is recruited, which then results in the activation of the NF-κB
transcription factor, as well as members of the mitogen-activated protein (MAP) kinase
family, which include: MAPK, c-Jun N-terminal kinase (JNK), and p38. TRAF6deficient mice have a defect in osteoclastogenesis, and develop osteopetrosis as a result
[30-32]. TRAF6 is the critical adapter in RANK-mediated osteoclast differentiation, and
the TRAF6/RANK interaction is a potential target for inhibition in the treatment of
various bone diseases, and might have implications in the areas of breast/lymph node as
well.
New evidence from copy number alterations shows that TRAF6 is an oncogene in
lung cancer. Overexpression of TRAF6 results in tumor formation and malignant
transformation of fibroblasts, and RNA interference (RNAi)-mediated knockdown of
TRAF6 decreases adenocarcinoma in two lung cell lines that have TRAF6 amplification
[33]. In these two lung cell lines, RAS required TRAF6 for its oncogenic capabilities.
This finding provides an explanation for constitutive NF-κB activation in RAS-driven
cases of lung cancer.
TRAF6 has been shown to play a major role in the signal transduction of
inflammation, cell survival and proliferation. Down-regulation of TRAF6 is beneficial in
a therapeutic setting, since there have been many implications of TRAF6 in different
disease states. TRAF6/RANK and their neighboring binding partners have been shown to
contain valid, druggable targets in two notable areas: The RANK/RANKL interaction and
TRAF6 decoy peptides. The RANK/RANKL portion of this pathway has seen
monoclonal antibodies against it in the form of Denosumab, which is an anti-RANKL
human monoclonal antibody developed by Amgen for use in the treatment of bone
4

loss/destruction due to rheumatoid arthritis, or metastatic cancers [34]. It is the first
RANKL inhibitor to be approved by the FDA, and it is showing promising results for
multiple myeloma with bone metastases [35]. Although germline deficiencies in
RANK/RANKL show strong B cell defects and it was suggested that RANKL inhibition
could trigger immunologic side effects, B cell specific RANK knockout mice in fact did
not show obvious direct defects in B cell physiology or development [36]. The other
notable area is that of cell-permeable peptides that bind to TRAF6 (TRAF6 decoy
peptides, referred to as T6DP) and have been developed that can target the
TRAF6/binding peptide interaction, and these have been shown to prevent RANK
signaling [15]. These peptides display specificity for the TRAF6-binding domains, and
the core motif (RKIPTEDEY) inhibited RANKL-mediated osteoclastogenesis and bone
resorption. RANKL-dependent activation of NF-κB undergoes a dose-dependent
inhibition upon pre-treatment with these decoy peptides, and primary mouse monocytes
differentiation into functional bone resorbing osteoclasts were blocked as well [37].
While these peptides are effective in blocking the interaction in experimental protocols,
their large size and potential sensitivity to endopeptidases renders them unsuitable as
clinical therapeutic agents. These decoy peptides might find future use when used in
liposomal or nanoparticle delivery techniques.
TRAF6’s role and mechanism in signaling in its diverse pathways becomes clear
when one examines its ubiquitin ligase activity. Ubiquitin ligases attach a small protein
called ubiquitin to target proteins; this ubiquitin can then induce either degradation of the
target protein (via the proteasome) or can promote interactions with other proteins that
result in signal transduction. Two main factors of ubiquitination allow for the
discrimination between degradation and signal transduction: the number of ubiquitin
5

proteins added (monoubiquitination versus polyubiquitination), and which specific lysine
residue that gets modified. Lysine48 (K-48) linked ubiquitination is recognized by the
26S proteasome and this ubiquitination triggers the protein degradation. Lysine63 (K-63)
linked ubiquitination is an important post-translational modification that can facilitate
various biological processes, including: activation of kinase signaling, endocytosis of
cellular receptors, protein localization and trafficking, and repair of damaged DNA [3840]. On TRAF6, the intact RING domain and the first zinc finger are required for K-63
auto-ubiquitination of TRAF6, and subsequent activation of downstream activation of
targets such as: IL-1, LPS, IKK, JNK, NF-κB, and osteoclasts differentiation via RANKL
signaling [41-43]. A recent crystal structure has shown the RING domain interacts with
the ubiquitin-conjugating enzyme (E2) called Ubc13, and that the first zinc finger has a
structural role in binding to Ubc13 [44]. Another significant finding in the ubiquitin
pathway is that Akt (the serine/threonine kinase, also called protein kinase B)
ubiquitination is triggered by TRAF6 E3 ligase activity. TRAF6 adds ubiquitin to Akt
and induces Akt ubiquitination in vitro and in vivo and is essential for Akt ubiquitination
and localization to the membrane where Akt is then phosphorylated and activated [45].
This ubiquitination of Akt occurs via the K-63 pathway and does not trigger Akt
degradation. Other kinases that are activated by TRAF6 K-63 ubiquitination are:
transforming growth factor-β-activating kinase 1 (TAK1) [46, 47], mixed linage kinase 3
(MLK3) [48], and interleukin-1 receptor-associated kinase (IRAK1) [49].
TRAF6 is a prime drug target candidate to inhibit using rational drug design. To
date, there are no known small molecule inhibitors of TRAF6 in the C-terminal region.
This is surprising, as the above data clearly show that TRAF6 is a highly significant and
valid target for the treatment of bone-related diseases. The discovery of TRAF6 as an
6

oncogene makes its use as a target even more appealing. The availability of highresolution crystal structures of the C-terminus of TRAF6 bound to both RANK and CD40 and the ineffectiveness of peptide-based treatments calls for the use of small molecule
inhibitors through structure-based drug design. The effectiveness of potential hits that are
discovered by this method can have their effectiveness compared to decoy peptides as a
positive control. From the publication describing the crystal structures, mutational
analysis was carried out to indicate which residues were required for binding to binding
peptides. Three residues on TRAF6 have been shown to abolish binding to CD40 (a close
analog to RANK) that shares the core motif as RANK; Arg392, Phe471, and Tyr473
(Figure 2); these residues can be considered hot spot residues [15]. These residues are a
good starting point for which to carry out structure-based drug design, as small molecule
inhibitors can interact with these hot spots and prevent formation of the TRAF6/RANK
complex. Using small molecules to inhibit the formation of protein-protein interactions is
a relatively recent technique, and hot spots have been used successfully to disrupt and
inhibit protein-protein interactions for a multitude of targets [50].
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Figure 2. Structure of TRAF6 (green) bound to RANK peptide (magenta).
Residues experimentally determined to be hot spots (Arg392, Phe471, and Tyr473)
are displayed as green sticks. Hydrogen bonds between RANK and TRAF6
displayed as dashed magenta lines. Figure generated in PyMOL.

In the current study, I will outline the steps that will aid in bringing a TRAF6
small molecule inhibitor closer to clinical relevance. In the hopes of developing TRAF6
as a valid target for small molecule therapeutics, computational prediction of hot spots
was carried out on the protein-protein interaction of TRAF6 and its binding peptides.
Three methods were used: Robetta, KFC2, and HotPoint, each of which uses a different
methodology to determine if a residue is a hot spot. These hot spot predictions were
considered the basis for resolving the binding site for TRAF6 in silico high-throughput
screening. Screens on the crystal structure of TRAF6 in complex with RANK will be
8

carried out using combined docking programs and our database of 10,000 drug/lead-like
compounds. Flexibility of side-chains that contribute significantly to the binding will be
considered. During hit selection, chemical diversity and drug-like properties will be
considered. Computationally intensive molecular dynamics simulations will be conducted
using GROMACS to determine the binding mechanism and TRAF6 structural changes
upon hit binding. Compounds identified as hits will be verified using a GST-pull down
assay, comparing inhibition to a RANK decoy peptide.
Since many drugs fail due to lack of efficacy and toxicity, predictive models for
the evaluation of the LD50 and bioavailability of our TRAF6 hits were developed, and
these models can be used towards other drugs and small molecule therapeutics as well.
Datasets of compounds and their corresponding bioavailability and LD50 values were
curated, and predictive QSAR models were built using molecular descriptors of these
compounds using the k-nearest neighbor (k-NN) method, and quality of these models
were cross-validated using leave-one-out cross validation.

Methods:
1. Computational Hot Spot Predictions of TRAF6
Since the three hot spots of the TRAF6/binding peptide interaction have been
described previously, computational prediction tools were used and compared to the
actual results, in an attempt to validate these predictions. Additionally, these predictions
can predict residues that are weak hot spots, or calculate potentials of residues that were
not biologically tested; these predictions were then used to guide the virtual screening.
The computational tools were: Robetta [51], an energy based computational alanine
9

scanning technique, HotPoint [52], a simple empirical model based on accessible surface
area, and KFC2 [53, 54], a knowledge-based and machine learning approach.
2. Preparation and Analysis of Target Receptor
The crystal structures of the C-terminal region of TRAF6 in complex with the
RANK and CD40 polypeptide were obtained from the Protein Data Bank [55] (1LB5 and
1LB6, respectively) [15]. These crystal structures display residues Gln347 to Thr501 of
TRAF6 (the TRAF6 sequence has 522 residues in total). 1LB5 was selected as the target
for virtual screening since it has the RANK peptide bound to the TRAF6 structure, and
the A chain was analyzed in complex with the B chain (RANK peptide) for virtual
screening. Structural water molecules were not considered to be significant to binding,
and these water molecules along with the B chain were removed from this 1LB5 structure
using PyMOL [56].
3. Chemical Library Selection
The dataset of compounds to be screened was the 10,000 compound MyriaScreen
Diversity Collection from Sigma-Aldrich in collaboration with TimTec. This was
selected for its high diversity and good drug-like and lead-like properties, as well as the
commercial availability of high-purity compounds. MyriaScreen was assembled from an
original pool of 300,000 Sigma-Aldrich and TimTec compounds, and TimTec’s
proprietary software was used to filter this original pool on the basis of diversity. Then,
additional filters were set to consider MW (>225 and <600), cLogP, H-acceptors, Hdonors, and rotatable bonds. 99.04% of compounds in the MyriaScreen collection satisfy
all four rules of the Lipinsky rule of 5 [57].
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The MyriaScreen chemical dataset (in .sdf file format) was minimized with root
mean square gradient of 1 x10-6 in MOE software from Chemical Computing Group [58]
based on MMFF94x (Merck molecular force field 94x) [59] and partial charges. The
MMFF94x force field is quite suitable for small molecules [60]. Minimization is required
to reach optimal energy levels for ligands before submitting them to virtual screening.
4. Virtual Screening
The MyriaScreen dataset was docked using GOLD from Cambridge
Crystallographic Data Centre (CCDC) [61, 62]. Hydrogen atoms were added using
GOLD program before docking was performed. The protein was treated as rigid, with no
amino acid side chains considered flexible. The binding site residues were manually
selected, and formed the cavity file. The residues selected were based on their proximity
to the RANK peptide co-crystallized with TRAF6: Arg392, Phe410, Met450, Leu456,
Leu457, Ala458, Phe459, Pro468, Lys469, Gly470, Phe471, Gly472, Tyr473, and
Val474. Ten genetic algorithm runs were selected for each ligand, and search efficiency
was set at 200% (double the default efficiency). Early termination of the docking of a
given ligand was performed (meaning GOLD advanced to the next ligand) if the top 3
solutions/conformations of a given ligand were within 1.5Å of each other. Although all
scores were kept, only the top 2000 GoldScore solutions/conformations were written out
as an SDF file.
5. Processing of Results
The results from the docking were then clustered based on structural MACCS
(Molecular ACCess System) fingerprints using MOE fingerprint clustering. The top 2000
GoldScored compounds were entered into MOE, and their molecular fingerprints were
11

calculated. The metric used was the Tanimoto coefficient. Similarity and overlap were set
at 80% to cluster similar compounds together. The result of this clustering was that
compounds that shared 80% of their total molecular features with other compounds were
merged into one cluster. For each cluster, the compound with the highest GoldScore in
that cluster was selected as the representative for that cluster, and the others in that cluster
were discarded. This clustering output contained 1619 compounds, indicating that 381
compounds had at least 80% similar molecular features but lower GoldScores than other
compounds in a single cluster, and these 381 were discarded.

6. Selection of Compounds for Biological Testing
From these 1,619 ligands, the top 300 ligands were selected for individual
molecular visualization and consideration. Each of the 300 ligands were individually
visualized (using PyMOL) in their docked conformation on TRAF6, and compounds
were selected for purchase and experimental testing via both pull-down and fluorescence
polarization assays.
Three main criterions were considered sequentially in this final selection process.
The first criterion was the degree to which the ligands’ conformation occupied the
interaction site between TRAF6 and RANK. If the ligands’ conformation primarily
existed outside of the interaction site, it was no longer considered a candidate. Second,
the following qualities: conformation, binding affinity, and resulting “fit” within the
TRAF6 binding site (compared to the corresponding RANK residues) were considered.
Each ligand, given its orientation in the docked position, was evaluated on its ability to
potentially block the binding of the RANK peptide. Along with these potential blocking
effects, we also considered the potential binding affinity of the ligand in its pocket. This
12

included qualities such as hydrogen bonds, static and aromatic effects that could be
formed from the ligand and TRAF6. The third and final consideration was the
distinctiveness of the molecular scaffold when compared to other ligands in the result.
The ligands were partitioned into “classes” based upon the individuality of their
underlying scaffold and how this scaffold was oriented in the binding site. Ligands that
shared a similar scaffold and orientation were considered to be in the same class, and
would then share the same class number. We then assigned a “priority” to each molecule
which was an aggregate of the second and third factors (conformation in the pocket and
distinctiveness). This priority was listed as: low, medium or high. The priority then
became similar to a degree of confidence for each ligand; compounds with “high”
priority were regarded as most likely to yield good biological activity, and should be
tested over the other low and medium confidence ligands.

7. Biological Testing
To test potential hits for their ability to inhibit TRAF6 functions, a GST-RANK
competitive inhibition assay was used. The procedure outlined here was provided by and
performed primarily by Professor Bryant Darnay from the department of Experimental
Therapeutics in MD Anderson Cancer Center. Human embryonic kidney (HEK) 293 cells
that stably express FLAG-tagged TRAF6 were harvested and lysed in lysis buffer (20
mM Tris, pH 7.4, 250 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate, 2 mM
EDTA, 1% Triton X-100, 2 µg/ml leupeptin, and 2 µg/ml aprotinin 20 mM) for 30 min
on ice. The cell lysate was centrifuged for 15 min and the supernatant was collected and
protein estimated. Equal amounts (150-200 µg) of protein lysate in binding buffer (20
mM Tris, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol, 0.1% Nonidet P-40 and 2 mM
13

EDTA) were mixed with the indicated compounds or TRAF6 decoy peptide 3 (T6DP3)
and allowed to rotate for 1 h at 4C, after which the samples were centrifuged for 5 min.
The supernatant was then mixed with bacterial purified GST-RANK-(340-358) bound to
glutathione-agarose beads for 2 h at 4oC with end-over-end rotation. The samples were
washed three times in binding buffer and two times in low salt buffer (20 mM TRIS pH
7.4, 25 mM NaCl, and 1 mM DTT). Bound proteins were then eluted in SDS-sample
buffer and boiled for 5 min, subjected to SDS-PAGE, and immunoblotted with antiFLAG [37].

8. Molecular Dynamics simulations
In order to describe the interactions of the hits that were identified in the
screening, I performed molecular dynamics (MD) simulations of the three hits in
complex with TRAF6, as well as a simulation of the TRAF6/RANK complex as a
comparison. GROMACS (version 4.5.3) was the software used, and explicit water was
used for these simulations [63, 64]. The force field selected was the GROMOS96 43a1
official distribution [65]. A cubic water box was created for the protein-ligand complex,
and the distance between the solute and the box was set at 0.9 Å. Charges were added to
neutralize the system to a formal charge of zero, and then the system was minimized
when the maximum force of the system was less than 10.0 kJ/mol. PME (Particle mesh
Ewald) algorithm was used for the long-range electrostatics for all simulations. For the
NVT (moles, volume, temperature) and NPT (moles, pressure, temperature) equilibration
the protein and ligand were considered as one entity (coupled together), and the ions and
water were also coupled together as one entity. This coupling was necessary, as the
system exploded (became highly unstable) not long after production MD started when
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this coupling was not present. Temperature was set at 298K, and the modified Berendsen
thermostat and Parrinello-Rahman were used for NVT and NPT coupling, respectively.
Periodic boundary conditions were set for x, y, and z directions. For each of these
production MD simulations, the bound conformations from GOLD were used as the
starting input, and the PRODRG server was used to generate topology (.itp) files for each
of the ligands [66]. All simulations were run for 20 nanoseconds. Jobs were run by
remote SSH terminal from my workstation into the Lonestar computing cluster in the
Texas Advanced Computing Center (TACC), using 144 cores [67]. Results were
extracted using VMD, and were analyzed using PyMOL [56, 68].

9. LD50 Predictive QSAR Modeling
A dataset of 7385 compounds and LD50 values for oral rat exposure was collected
from a previous study by Hao Zhu et al. who were attempting to achieve the same
endpoint; the details of how that dataset was collected are described in the following
section [69]. A dataset of more than 8000 compounds and corresponding LD50 (oral rat
exposure) from the ChemID plus database was collected, and the structures of these
compounds was verified using an method discussed by Young et al. [70]. Zhu’s group
removed the inorganic, organometallic compounds, salts, and compound mixtures. They
also converted the LD50 values from mol/kg to log(mol/kg) values according to standard
QSAR practices [69]. Various descriptors were calculated including those from the
Dragon software v5.4 [71], MOE [58], and cxcalc from ChemAxon [72]. These
descriptors were then used with the kNN-QSAR method to provide the models [73]. The
kNN-QSAR method was used to generate the predictive models.
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10. Bioavailability Predictive QSAR Modeling
A dataset of 809 compounds was collected from two publications: 768
compounds from Hou et al. and from Veber et al., these two datasets were merged
despite having many similar entries [74, 75]. The values were often taken from the
literature; single values were recorded as-is, whereas when a range of values was
reported, a simple average was used as the percent bioavailability [76]. For example, if a
value was reported as 0-20% bioavailability in Goodman and Gilman’s, the value used
was considered 10%. Descriptors for this data set were calculated in an identical manner
to the LD50 data set, and the kNN-QSAR method was also used to generate the predictive
models.

Results:
1. Computational Hot Spot Predictions of TRAF6 - Results
Robetta uses a simple physical model and a computational alanine scanning
technique that includes various energy and chemical bonding parameters such as:
Lennard Jones interactions, packing and solvation terms, and hydrogen bonding to
calculate free energy [51]. Computational alanine scanning involves mutation of a given
residue involved in a protein-protein interaction to alanine (a non-reactive and non
charged side chain) of one of the interacting proteins, and computing the resulting change
in binding energy of the interface. If this mutation results in a significant decrease in the
binding constant (typically tenfold or greater), this residue is considered a hot spot [77].
Robetta mutates the residue to alanine for each residue, and then it locally repacks other
residues in the structure within 5Å of the mutant residue, maintaining the conformation of
16

the remaining protein residues. The predicted changes in binding energies from this
computational alanine scanning constitute the foundation for Robetta’s hot spot
predictions [78]. Robetta provided the most accurate (indeed a perfect score) of the hot
spots on TRAF6, with all three experimental hot spot residues in the structure having a
predicted ΔΔG greater than 1 kcal/mol (Table 1). The Arg392 position is predicted to be
a very active hot spot with a ΔΔG value much higher than the other two correctly
predicted hot spots; from this prediction, one can infer that rational design around this
residue is likely to give a better inhibitor of the TRAF6/RANK complex, since it
contributes the most to binding of the RANK peptide. Values that are positive (or more
positive) for the ΔΔG of the TRAF6/RANK complex indicate that a destabilization of the
complex occurs when a residue is replaced by alanine; the other predictions do not show
such a change in energy; hence they are not predicted to be hot spots. It is interesting to
note that the next highest (and closest to 1.0 kcal/mol) ΔΔG value predicted by Robetta is
the Phe410, with a value of 0.76 kcal/mol. This residue was later shown to be important
to binding by the molecular dynamics results.
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Num Residue int_id ΔΔG(complex) ΔG(partner)
374

Val

1

0.36

1.04

376

His

1

0.44

0.32

392

Arg

1

3.76

1.51

410

Phe

1

0.76

3.21

412

His

1

0.4

2.61

448

Glu

0

-0.03

-0.12

450

Met

1

0.13

2.38

453

Lys

0

-0.12

0.08

456

Leu

1

0.48

1.34

466

Arg

1

0.07

0.94

469

Lys

1

0.62

-0.14

471

Phe

1

2.05

1.65

473

Tyr

1

1.73

1.8

474

Val

0

0.07

0.43

Table 1. TRAF6 Hot Spot predictions from Robetta.
Num: residue number. Residue: three-letter code for amino acid. int_id: Binary
descriptor of if a side chain of a residue is present within 4 Å of another
partner’s atom (1) or not having a contact directly, but is buried upon binding
(0); ΔΔG(complex): Prediction of binding free energy change upon mutation of
alanine; ΔG(partner): Predicted change in stability of protein of the
corresponding mutated partner complex upon subsequent alanine mutation.
Residues highlighted yellow are biologically proven hot spots. If ΔΔG(complex)
is greater than 1.0 kcal/mol, they are considered a hot spot by Robetta.

KFC2 did not have as successful of a prediction as Robetta. KFC2 is comprised of
two models, KFC2a and KFCb, each having their own parameters. KFC2a offered no
predictions for this structure, and KFC2b was adequate in providing correct hot spot
predictions of Arg392 and Phe471, but provided two false positive results of Phe410 and
His412. KFC2b also did not label Tyr473. Both KFC2 models label a residue a hot spot
when the confidence of either method is a non-negative number (Table 2).
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Hotpoint’s predictions were identical (in terms of false positives and false
negatives) to those from KFC2, predicting Arg392 and Phe471 correctly, but not labeling
the residue Tyr473 and providing a false prediction of Phe410 as a hot spot (Table 3).
The potential value on Arg392 was the highest among all of the residues that were
considered interacting. Hotpoint did not predict His412 to be a hot spot, but did predict
Met450 as one. This Met450 residue lies close to the aromatic residues of Phe471 and
Tyr473, and is significantly buried.
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Num

Res

KFC2-A Class

KFC20-A Conf

KFC2-B Class

KFC2-B Conf

374

Val

0

-1.78

0

-0.99

376

His

0

-2.18

0

-0.98

392

Arg

0

-0.37

Hotspot

0.15

394

His

0

-1.9

0

-0.95

410

Phe

0

-0.43

Hotspot

0.23

412

His

0

-0.63

Hotspot

0.05

448

Glu

0

-2.31

0

-0.98

449

Ile

0

-2.39

0

-0.92

450

Met

0

-1.42

0

-0.26

451

Asp

0

-2.32

0

-0.96

453

Lys

0

-1.77

0

-0.96

456

Leu

0

-1.25

0

-0.83

457

Leu

0

-2.37

0

-0.94

458

Ala

0

-0.84

0

-0.76

466

Arg

0

-1.8

0

-0.79

468

Pro

0

-0.88

0

-0.8

469

Lys

0

-0.79

0

-0.56

470

Gly

0

-0.22

0

-0.46

471

Phe

0

-0.17

Hotspot

0.28

472

Gly

0

-0.38

0

-0.59

473

Tyr

0

-0.87

0

-0.04

474

Val

0

-1.24

0

-0.95

475

Thr

0

-1.83

0

-0.99

Table 2. KFC2 prediction of hot spots on TRAF6.
Num: residue number. Res: three-letter code for amino acid. Model
classification and predictions of two KFC models (A or B model); (Conf):
Confidence of prediction. Residues highlighted in yellow (Arg392, Phe471,
Tyr473) are experimentally proven hot spots.

20

Num

Residue

RelCompASA

RelMonomerASA

Potential

Prediction

374

Val

36.17

50.36

12.38

0

376

His

29.78

35.89

18.13

0

392

Arg

1.34

22.39

25.64

Hotspot

410

Phe

1.94

11.86

28.55

Hotspot

450

Met

1.76

6.09

33.49

Hotspot

456

Leu

21.77

35.29

11

0

457

Leu

61.09

62.37

7.59

0

458

Ala

2.41

5.39

13.8

0

468

Pro

37.32

74.16

4.79

0

469

Lys

25.35

53.96

8.9

0

470

Gly

0.19

29.14

12.76

0

471

Phe

1.22

22.9

37.55

Hotspot

472

Gly

0.45

35.78

16.16

0

473

Tyr

7.52

27.91

17.22

0

Table 3. Predictions of TRAF6 hot spots from Hotpoint.
RelComp ASA: Relative ASA of complex structure. RelMonomer ASA:
Monomer Relative ASA. Residues in yellow (Arg392, Phe471, Tyr473) are
experimentally proven hot spots.
KFC2 and Hotpoint both were lacking in their prediction of Tyr473 as a hot spot,
despite both methods having values that were close to the cutoff values to change the
prediction form non-hot spot to hot spot. The confidence of Tyr473’s prediction in the
KFC2b model very close to the threshold; this residue had the smallest negative value
among the other residues in the list. The only reason Hotpoint’s prediction did not
mention Tyr473 as a hot spot was due to the potential factor; the value was not greater
than 18.0. The false positives from Hotpoint (residues Met450 and Phe410) stem from
the relative high potential, and not from the accessible surface area metric. As was
mentioned before, Phe410 and Met450 were in fact tested at the same time as the other
residues, and were not proven to be hot spots [15]. This conclusion does not mean that
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they have no contribution to the complex, but that they do not meet the experimental
cutoff value of a hot spot. Since both programs scored the Phe410 and Met450 residue
very close to a hot spot, both these residues should not be ignored as they will likely
contribute to the binding, albeit not significantly (at least to the RANK peptide).
2. Virtual Screening
In GOLD, the default scoring function is the GoldScore; this is comprised of four
components from the equation:

f = S hb _ ext + S vdw _ ext + S hb _ int + S vdw _ int
Where Shb_ext is the protein-ligand hydrogen bonding score and Shb_int is the
internal hydrogen bonding of the ligand. Svdw_ext and Svdw_int are the scores arising from
weak external and internal Van der Waals forces, respectively. The scores from the
virtual screening approached an extreme value distribution (Figure 3)
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Figure 3. Histogram of TRAF6 virtual screening results (GoldScores) from GOLD.
The highest GoldScore was 75.18 and the lowest was 18.31. The average was 40.30
for the GoldScore.

3. Selection of Compounds for Biological Testing, and Biological testing
The technique described above resulted in 300 compounds for consideration for
biological testing. The first round of selected compounds was limited in the number of
compounds that were to be tested, and only seven compounds were selected for testing
(Table 4). These first seven tested compounds were found to be not active when tested at
100µM and 300µM (Figure 4).
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Table 4. First set of selected compounds for biological testing.
Test ID values were assigned from decreasing GoldScore from the list of 79 compounds.
GOLD: GoldScore output from GOLD. logP: calculated log of octanol/water partition
coefficient. All seven of these were shown to be inactive via GST pull-down assay.
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Figure 4. GST-RANK pull down assay for first round of seven selected compounds.
DP is the positive control decoy peptide, and C is the negative control (no peptide).
After discovery that the first set of compounds were not active, the docking
results were examined once again, this time with emphasis on the Arg392/Phe410
binding site. The reasoning was that it was this region (not the Phe471/Tyr473 region)
that might be more significant to the binding of compounds to TRAF6. The second round
of compounds were taken from the pool of 79 compounds, but compounds to be selected
for the second round were those compounds that had a more favorable binding to this
region. Twenty compounds were selected for the second round of testing (Table 5),
(Table 6), and (Table 7) using the same technique as the first round of compounds, but
were to only be tested at 200µM (Figure 5). While the concentration of the ligands was
high, there does seem to be some reduction in the binding of the compounds SZB-40,
SZB-45, and SZB-46.
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Table 5. Second set of compounds to be tested.
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition
coefficient. Test ID: assigned names from list of 79 compounds.
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Table 6. Second set of biologically tested compounds (continued).
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition
coefficient. Test ID: assigned names from list of 79 compounds.
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Table 7: Second set of biologically tested compounds (continued).
GOLD: GoldScore output from GOLD. logP: calculated log octanol/water partition
coefficient. Test ID: assigned names from list of 79 compounds. SZB-40, SZB-45,
and SZB-46 showed some activity.
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Figure 5. GST-RANK pull down assay for first round of selected compounds.
DP is the positive control decoy peptide, and C is the negative control (no peptide).
Compounds 40, 45, and 46 appeared to have some activity.

Molecular Dynamics simulations
GROMACS simulations were run for 20 nanoseconds compound SZB-40, SZB46, and for the RANK peptide (as a control and comparison). SZB-40, which appeared to
have the best binding score from GOLD, did not have as significant of a binding energy
when compared with the RANK peptide (Figure 6). This figure shows the short range
Lennard-Jones energy of the protein-ligand complex. The average energy of the run of
SZB-40 was -177kJ/mol, while RANK had energy of -257 kJ/mol; standard deviations
were 20.86 and 28.10 for SZB-40 and RANK, respectively.
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Figure 6. Lennard-Jones energies for molecular dynamics simulations.
TRAF6-ligand complex (kJ/mol) of SZB-40 (blue), SZB-46 (red), and RANK
peptide (green) for the entire 20 nanosecond molecular dynamics simulation.
Output of energies was performed for each trajectory, and the output was graphed
in Excel.

The two simulations produced roughly similar RMSD values, the control RANK
simulation deviating at an average of 0.239Å from their main chain, and the SZB-40
RMSD equal to 0.196Å, indicating that the overall stability of the structure was not
significantly affected by the ligands. The standard deviation of main chain of the
structures was 0.0399 Å for RANK, 0.0288 Å for SZB-40.
The region of the 9,000 to 13,000 picoseconds (9 to 13 nanoseconds) is
interesting, as it shows better energy values. Output of trajectories at every 2,000
picoseconds was carried out for the entire simulation, in order to evaluate the differences
that occur between SZB-40 and the TRAF6 structure throughout the MD run. The
trajectory at 10 nanoseconds shows a very interesting conformation (Figure 7). It appears
that the ligand has achieved pi-stacking with the aromatic residues Phe470, and there is
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also a pi-stacking interaction to the Phe410 residue. There are hydrogen bonds to two
points on the main chain of Gly469, similar to that of RANK. It is interesting to note that
many portions of the MD simulation run showed the ligand on the side of TRAF6 closer
to the Phe471 residue. This conformation was not possible in the GOLD
screening/docking, as only the side chains are flexible; the GROMACS MD simulation
shows a more favorable position to those that were seen from the GOLD docking.
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Figure 7. Sample trajectory conformation at mid-point (10 ns) of MD simulation of
SZB-40 (pink) and TRAF6 (green). Yellow dashed lines with numerical labels
denote distances to neighboring aromatic groups. Hydrogen bonds to main chain
atoms on Gly469 to SZB-40 are shown in unlabeled yellow dashed lines. This
conformation was close to the average structure over the 9-11 nanosecond range,
and it shows a more favorable pose to docked positions, with pi-stacking of both
aromatic ends of SZB-40 to other aromatic groups on TRAF6. The distance from
SZB-40 to Phe410 is 4.0 angstroms, and Phe410 was predicted as a hot spot by
HotPoint and KFC2.
Another sample output was taken at the 12,000 picoseconds (12 nanoseconds),
which is also in the region of lower energy. One would assume that this lower energy
state would correspond to a more favorable docked position similar to that of the 10
nanosecond point, and this is indeed the case (Figure 8.). This is similar to that of the 10
nanosecond point, but there is additional hydrogen bonding to Gly471 (which lies in
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between Tyr472 and Phe470. This state should have an even tighter binding to TRAF6,
and this might explain why SZB-40 was shown to be active.

Figure 8. 12 nanosecond sample trajectory of SZB-40 (pink) and TRAF6 (green).
Yellow dashed lines denote distances to neighboring aromatic groups. Hydrogen
bonds are shown in yellow dashed lines without distance labels. Note the more
extensive hydrogen bonding to both Gly469 but also to main chain atoms on Phe471.
This interaction is also more favorable to docked positions seen from GOLD.
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4. LD50 Predictive QSAR Modeling
A histogram of the compounds shows a good distribution of values, and
approaches an extreme value distribution (Figure 9). After the kNN-QSAR models were
generated at various parameters, the predictive model with the best cross validated r2 (q2)
had eight descriptors and were as follows: logPWeighted, smallestRingSize,
acceptorCount, ASAPolar, topologicalPolarSurfaceArea, chainAtomCount, atomCount,
and hararyIndex. These descriptors are primarily associated with size, logP, and
accessible surface area. The number of nearest neighbors for this highest rated model was
three (k = 3), and this model had a q2 value of 0.324 in the training set, and a
corresponding r2 of 0.6252 for the 385 compounds in the test set. The distribution of the
actual versus predicted values can be seen when plotted (Figure 10).
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Figure 9. Histogram of negative log of LD50 values (mol/kg) of 3472 compounds.
The highest value was that of tetrachlorodibenzo-p-dioxin (TCDD), with a value of
10.2, while the lowest was 6-methyl uracil, with a value of 0.29. The average value
was 2.466. Data was transformed and graphed using Excel.
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Figure 10. Actual vs. Predicted LD50 values from best kNN-QSAR model.

5. Bioavailability Predictive QSAR Modeling
While the values for bioavailability were well distributed (Figure 11), the
bioavailability model did not perform as well. There are 22 descriptors for this model,
these were all generated from MOE, and they are as follows: randicIndex, FASA_H,
PEOE_VSA_FPPOS, pmiY, vdw_vol, SMR_VSA2, Q_RPC-, PEOE_VSA_FPOL,
PEOE_VSA-2, vsurf_HB2, PEOE_VSA+3, b_1rotR, carboRingCountOfSize,
logDPHYS, SMR_VSA1, aliphaticRingCount, chi1v_C, a_ICM, SlogP_VSA0,
BCUT_SMR_3, GCUT_SLOGP_2 mr, and BCUT_SLOGP_1. There are four nearest
neighbors, and the q2 is 0.363177 for 414 compounds, and the r2 is 0.123 for 306
compounds (Figure 12).
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Figure 11. Histogram of 809 bioavailability values used in the predictive model.
The data set has good distribution over the range of possible values with a very
slight bias towards high values: the average value is 52.0 and median value is 54.
Graph was generated in Excel.

Figure 12. Actual vs. Predicted bioavailability values from kNN-QSAR model.
This is the r2 test set, with 414 compounds. Values were taken from the output of the
best quality model, and were graphed in Excel. The low quality of the data used in
this model adversely affected the predictive quality of the model itself.
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Discussion:
1. Computational Hot Spot Predictions of TRAF6
The TRAF6/RANK pathway is typical of most biological cellular functions, in
that a protein-protein interaction is required to retain functionality [79]. Broadly
speaking, formation of protein-protein interactions necessitate particular contacts and
interactions which form the foundation for almost all biological functions, most notable
of these are events are signal transduction events. Protein-protein interactions are seen as
having locally primed features optimal for the binding of their partners, and they form
highly conserved and dense networked clusters contributing cooperatively to the
complex’s stability [80]. The interaction sites of these protein-protein pairings are made
up of surfaces that contain electrostatic and shape complementarity properties [81-84].
Protein-protein interactions can also be drastically influenced by the inherent properties
of their residues, such as hydrophobicity and flexibility [82-86]. Some protein-protein
interfaces have been described with relatively small areas, with surfaces as small as 11501200 Å2 for structures such as complexes forming low-stability and short-lived regions.
So called “standard-size” surfaces of interaction [87] fall into the region of 1600 Å2 (±
400 Å2) and involve relatively small conformational fluctuations and side-chain
movements upon forming said complexes[88]. “Large” interfaces involve 2000 to 4600
Å2 , and require significant, global changes in the interacting members, and are seen
primarily in G-protein receptors and family members, as well as information processing
elements of signaling proteins. Using the DMBL-EBI PDBePISA (Protein Interfaces,
Surfaces and Assemblies) server [89], the TRAF6/RANK complex is shown to have a
very small interface area, being only 557.8 Å2 in size. The TRAF6/CD40 complex
(1LB6), has a slightly larger surface area, with 573.1 Å2. This means that the
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TRAF6/RANK complex is very small and unstable, and very little changes in either
structure are expected to occur when binding takes place.
The three methods used to predict hot spot residues used a variety of techniques,
and each has been successful in other test sets of proteins. Robetta achieved a perfect
score in its prediction of the TRAF6 residues, and in another study, correctly predicted
79% of residues with a 1.0 kcal/mol cutoff (indicating they are in fact hot spots) with an
error averaging to the value of 1.06 kcal/mol [78, 90]. While this method was the most
successful in predicting hot spots of the TRAF6/RANK complex, there is one potential
source of error in the implicit solvation model used by Robetta and for other predictions:
hot spots that are mediated from water molecules can potentially compensate for
particular alanine mutations, and can potentially give a false positive result. Since the
waters were removed from this complex before submitting to Robetta, this was not an
issue.
HotPoint is based on work that was done by Tuncbag et al. it uses primarily
accessible surface area (ASA) and includes factors for conservation and pair-wise
potentials of the residues to form an empirical model. This model has been recorded at
70% accuracy, when using 150 residues from ASEdb as the training set; this accuracy is
higher than many machine learning based methods [91]. This technique was implemented
into a publicly available web server, also named HotPoint, where visitors can register and
submit a job and easily visualize the output prediction on any compatible browser [52].
Accessibilities to the solvent for each residue are computed for each form (bound and
unbound), and the energetic pair-wise potential contributions from the solvent were
provided by Keskin et al [92]. If and only if the following two endpoints are satisfied: the
relative ASA in complex is equal to less than 20%, and the summation of the potential for
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a given pair is greater or equal to 18.0, then that residue is classified as a hot spot [52].
The mutation of solvent accessible surface area (ΔASA) when a complex is formed for
two proteins has a high degree of correlation to the energy of solvation. This factor was
previously identified to be highly predictive versus other factors towards that of the
binding of protein partners [93]. The same group also developed a database from this
technique, called HotSprint, and was successful in predicting hot spots on the p53 binder,
Mdm2. An accuracy of 76% was achieved, which can out-compete many popular
methods that rely on machine-learning approaches [94].
KFC2 (Knowledge-based FADE and Contacts, by Darnell, Zhu, Page, and
Mitchell [53, 95] ) uses a support vector machine (SVM) [96], machine-learning method
to build two models, each of which are decision tree-based. Each model is built on two
techniques: the first one is named K-FADE, it uses the size of a given residue and the
specificity of its shape that are calculated by Fast Atomic Density Evaluation (hence the
name FADE) [97], and K-CON uses the residue’s hydrogen bonds, chemical types,
interface points, and intermolecular atomic contacts [54]. These features are combined to
output an answer in binary form to the question of if a residue is a hot spot or not, and
provide a corresponding confidence score with this binary prediction. KFC2 has two
models trained on SVM: KFC2a and KFC2b. The KFCa model was shown to have 0.85
as its rate of predicting hot spots correctly. This value was an improvement from the
previous KFC method, as well as other predictions from HotPoint, Robetta, and
FOLDEF, despite KFCa possessing a greater rate of incorrectly labeled hot spots than
these competitors. KFC2b uses a total of seven features (overlapping two of the features
from KFCa), and is seen to output a specificity greater than KFCa [53]. It is interesting
that despite KFC2a’s higher reported sensitivity and accuracy when compared to KFC2b,
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no hot spots were predicted for the TRAF/RANK complex with KFC2a. It is also
interesting that while the KFC2a model predicted no hot spots on TRAF6, the KFC2b
model appears to have had both a high true positive, and a higher false positive rate.

2. Preparation and Analysis of Target Receptor
Selection of crystal structures 1LB5/1LB6 was necessary since both have the
RANK/CD40 peptides bound to them. The remaining C-terminal 21 residues at the end
of the crystal structure that are not included but exist in the TRAF6 sequence do not lie
close to the RANK/CD40 binding site. The shortest distance from Thr501 to the RANK
peptide is 16.4Å. Also, Thr501 ends a β-sheet, so the remaining residues of the structure
are likely in a loop region that either interacts with the other loop regions in this area, or
with the long helix that forms in the TRAF6 trimer (Figure13)
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Figure 13. C-terminal Thr501 residue in TRAF6 1LB5 crystal structure (green).
RANK residue shown in magenta sticks. This threonine residue lies at least 19
angstroms to the RANK binding site; remaining residues on this tail are unlikely to
have an effect on the binding site.

1LB5 was selected as the structure for which to do docking, since it contains the
RANK peptide bound to TRAF6. [15]. While the TRAF6-CD40 complex of 1LB6 has a
slightly higher resolution (1.80Å), it is very similar to 1LB5 (resolution of 2.40 Å). The
RMS of the two structures (when superimposed) is only 0.294 Å, and this difference is
mainly in the loop regions of the two structures. The only TRAF6 residue in the binding
site that is significantly different in its conformation is the Arg392 residue (Figure 14).
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Figure 14. Superimposed overlay of 1LB5 (green) and 1LB6 (blue) structures.
Hotspot residues are displayed in sticks. Tyr473 and Phe471 are nearly identical in
their conformation, while Arg392 is rotated significantly.

3. Chemical Library Selection
The choice of MyriaScreen as the primary ligand screening set ensured that
adequate chemical diversity was present in the virtual screening, while retaining good
drug-like and lead-like structures. Additionally, MyriaScreen compounds are easily
commercially available, making for easy procurement and testing of the selected
compounds.
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4. Virtual Screening
GoldScore fitness function was selected as the scoring function, as it has been
created and optimized for small molecule docking into the prediction of ligand binding
energy. GOLD has proven to be a more than acceptable program for various techniques
when compared with other docking programs [98-100], and it has been shown to be
capable of reproducing reliable docked conformations of ligands for many of my other
projects. The program is able to run on a multi-core environment, which is favorable to
other methods that are more computationally expensive.

5. Processing of Results
The clustering of the GOLD results based on MACCS fingerprints removes
similar compounds and increases the diversity of the pool of molecules by removing
structurally similar compounds. Retaining the highest scoring representative structure of
each cluster ensures the quality of the docked conformations is retained, but repetitive
structures are discarded. This technique also ensures that the highest scoring
representatives of each of the compounds is retained and selected as the best
representative of the respective chemical core and binding pose.

6. Selection of Compounds for Biological Testing
As for the selection of the final hits, the technique used here has been used in
various other projects. The cluster centers were individually visualized by hand in
PyMOL to maximize the potential of finding ligands that would prove to be active
biologically. This higher scrutiny at this stage not only ensured that there was more than
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adequate diversity in the final compounds; it confirmed that the compounds resided in the
desired interaction site and therefore had a high potential of inhibiting the interaction
with RANK. Also of note, our analysis was independent of the docking scores obtained;
this made for our analysis to be more qualitative than quantitative.

Flexible Docking of three active compounds
The three compounds that showed affinity (SZB: 40, 45, and 46) were submitted
to a more rigorous GOLD docking, in which the ten closest residues to their original
conformation were allowed to have their side chains be fully flexible; this process
permits a deeper understanding of the potential interactions between the hits and TRAF6.
For these docking jobs, GOLD was again used as the docking program, and the number
of operations and population size of the genetic algorithm were doubled from the original
virtual screening protocol.
Although the SZB-40 compound contains a ring structure that can gain stability
by pi-pi stacking in between Tyr473 and Phe471, the flexible docking did not show such
a conformation (Figure 15). Instead, there was main chain hydrogen bonding seen
between Gly470 and His412. But the most significant difference in the side chains (due
to the flexible docking) is seen in the Arg392 and Arg466 residues. There are two
hydrogen bonded interactions to the Arg392 and this is stabilized by the pi-stacking of
the terminal (non-chlorinated) benzene structure of SZB-40 to Arg466. The movement of
these two structures between the original structures creates a more favorable pocket.
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Figure 15. Flexible GOLD docking of SZB-40 (pink) to TRAF6 (green).
Hydrogen bonds are shown as dashed yellow lines. This conformation show a weak
pi-stacking to the Arg466 residue, and main chain hydrogen bonds to the Gly470
and Phe471, but no significant interactions to the aromatic Phe410, Phe471, or
Tyr473 residues.

SZB-45 was similar to SZB-40 in that it also had a moiety by which to mimic the
proline structure on RANK in the pi-pi stacking interaction between the Tyr473 and
Phe471 residues, but this conformation was not seen in the docking results (Figure 16).
This structure had much more extensive binding to the Arg392 and Arg466 structures
(from the highly charged sulfonamide region) at multiple locations on each of these
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residues. There is also a hydrogen bonding interaction with the Asn467 main chain.
There appears to be a pi-stacking interaction with the Phe410 moiety; this somewhat
validates the prediction of Hotpoint and KFC2, which both predicted this residue as a hot
spot. Robetta calculated this residue’s ΔΔG of the complex with a value of 0.76 kcal/mol.

Figure 16. Flexible docking of SZB-45 (blue) to TRAF6 (green).
Hydrogen bonds shown as dashed yellow lines. Main chain hydrogen bonding
interactions are seen to Asn467 and side chain hydrogen bonds are seen to the
Arg466 and Arg392 residues. There is also a good pi-stacking interaction with the
Phe410 residue.

As for SZB-46, this conformation seems to have a better opportunity for pistacking in between the two aromatic structures, and it also is stabilized by the two
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arginine groups (Figure 17). Additionally, the hydrogen bonding interactions with the
Gly470 are similar to that of RANK, and there are two hydrogen atoms on the Lys469
structure that share hydrogen bonds with two different carbonyl regions of the SZB-46
ligand.

Figure 17. Flexible docking of SZB-46 (blue). Hydrogen bonds shown in yellow.
This conformation shows side chain hydrogen bonds to Arf466, Arg392, and main
chain bonds to Gly470 and Phe471. There is also a good pi-stacking interaction to
Phe410.
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7. Biological Testing
The GST-RANK pull down assay did manage to show an inhibition of three of
the hits on the second round of testing, but as this method is more qualitative than
quantitative, it is difficult to elaborate on the results beyond what is apparent from the
Western blot. Further testing is required (preferably one that can be quantized) using
another technique, possibly an ITC or luciferase assay.

8. Molecular Dynamics simulations
The choice of GROMACS as the molecular dynamics (MD) package was an easy
one, as GROMACS is very flexible and widely used software [64]. GROMACS has been
shown to be much more efficient than other MD programs, and scales very well on large,
parallel computing clusters [101]. It has been shown that the topologies resulting from the
PRODRG server can deviate from simulations from GROMOS parameters, and
reasonable configurations can be achieved using this method [102]. When the average
back bone structure of the MD simulation is output from the MD simulation and then
aligned to the original 1LB5 crystal structure, the RMSD is only 1.346Å, and this
difference lies only in the loop regions, not in the β-sheet region (Figure 18). It is
reasonable to assume that the stability of the β-sheet sandwich in TRAF6 is highly stable
in the explicit water solvent used here. Hence, the GROMACS molecular dynamics
method appears to be a good system on which to compare the result of this and future
TRAF6 inhibitors.
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Figure 18. Alignment of cartoon structures of MD simulation of TRAF/RANK.
Average structure (backbone atoms) of results of MD simulation (blue), 1LB5
structure TRAF6/RANK complex (green). RMSD of these structures is 1.346Å. The
three hot spot residues are shown as sticks as a point of reference. Output for the
simulation was prepared using Gromacs, and the structures were aligned using the
“align” feature in PyMOL.

9. LD50 Predictive QSAR Modeling
The large size of the dataset was a potential hindrance in the production of better
models, but considering the variability of the data, the models were able to achieve a
general prediction as to the magnitude of the endpoint which was attempted to be
modeled. While most of the data is from oral testing of rats, the species and weights of
these rats is not available. What is interesting (and perhaps contradictory to the previous
statement) is that selecting only the less toxic compounds (removing the top 10% most
lethal compounds from the data set) actually produced worse models than the one
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presented here. The model presented includes highly lethal compounds like several forms
of polychlorinated dibenzodioxins (dioxins), and the nerve agent O-ethyl-S-(2dimethylaminoethyl)-methyl-phosphonothioate (EDMM). Since lethality can manifest in
different forms (inhibition of protein synthesis, mitochondrial damage, blocking of
critical ion channels, DNA damage, to name a few), there are many different structural
cores that are present in the dataset. These different structural cores and their
corresponding mechanisms of lethality are likely creating confusion in the models. A data
set that only contained ion channel disruptors is more likely to produce a good model of
lethality, but would not be representative (or applicable) to other, more diverse
compounds. Despite the variability of the data, logP is known to be a major factor in
toxicity, as non-polar structures are much more likely to be metabolized and excreted (as
well as be handled by the acidic gut) before their toxicity can become apparent.

10. Bioavailability Predictive QSAR Modeling
The inconsistencies in the original data set definitely hurt the quality of the
models generated, it is apparent that there is over fitting of the data, and the number of
descriptors seen in the model (especially when compared with the LD50 model) backs this
assumption up. Variability in the dosing, formulation, pharmacogenomics
(polymorphisms in efficacy and other pharmacokinetic properties), health of the subjects
and sampling error when recording the bioavailability data will all lead to a
corresponding decrease of the quality of the models, and this is most likely what is seen
here. It appears that such a complex endpoint in humans is difficult to model with simple
tools, and classification schemes will likely lead to better predictive models. The strength
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of using a kNN based model such as the one that was used here is that it is nonparametric; there are no assumptions made on the distribution of the data set.

Conclusion:
In this study novel inhibitors of the TRAF6/binding peptide interaction site are
presented that were discovered through a rational design process incorporating various in
silico techniques. From an initial set of 10,000 compounds, 26 of them were tested. Three
of these 26 compounds were shown to be biologically active. These results validate the
virtual screening and biological methodology described here, as well as validates the
TRAF6/binding peptide interaction as a potential target for small molecule inhibition.
The results here lay the framework for future study of inhibition of the
TRAF6/binding peptide interaction, and further study of the binding mechanism (either
by crystallization of the inhibitors in complex with TRAF6, or by other biological
experiments) will reveal means of optimizing the inhibitors for use in clinical settings.
Future studies of the generation of TRAF6 inhibitors will surely benefit from additional
assays for which to test the activity and mechanism of binding. Techniques such as a
luciferase assay or isothermal titration calorimetry (ITC) would bolster the evidence of a
possible inhibitor from the initial GST assay described above. Once a decent inhibitor has
been found, optimization of the respective chemical groups can increase the binding
affinity even further. While the TRAF6/binding peptide protein-protein interaction is a
very valuable target, it is a difficult one. The binding site is not a prototypical pocket that
is conducive to traditional drug design efforts, and the interaction site, despite being
small for protein-protein interactions, is large for small molecule inhibitors to bind to. In
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general, targeting protein-protein interactions are high-risk and high-reward, but the
TRAF6/binding peptide interaction is beyond the exemplary target and has even higher
potential value. Computational techniques such as the ones that I have outlined here (hot
spot prediction, virtual screening, and molecular dynamics simulations) will help to
ameliorate the risk involved by guiding the decisions throughout the drug design process.
Given that TRAF6 plays many essential roles in immunity and other diverse
biological functions, TRAF6 inhibitors are most certainly in high demand. Not only will
they serve to advance the understanding of the TRAF6 pathway, but has the potential to
improve the lives of patients through controlling inflammation and treating a wide range
of diseases, such as: osteoporosis, cancer-induced bone lesions and other bone diseases,
postmenopausal osteoporosis, multiple myeloma, periodontitis, connective tissue
destruction, bladder outlet obstruction, Paget’s disease, and viral infections [103-105]. On
the front of cancer therapeutics, it has been postulated that TRAF6 inhibitors should be
able to inhibit the spread of multiple myeloma and prevent bone loss (the most significant
clinical manifestation of MM). These inhibitors will mean the inclusion of a new target
for the treatment of cancer, and will be able to overcome resistance to chemotherapy
[106]. There are still more questions as to the TRAF6 pathway, most notably the specific
activation mechanism of TRAF6. It is unknown if TRAF6 is monomeric before
recruitment to its receptors; additionally it is unclear if it is the TRAF6 oligomerization or
the resulting conformational changes from oligomerization that guide the subsequent
activation of TRAF6 [107]. These questions, as well as understanding how ubiquitination
plays a role in TRAF6 activation, need to be answered to complete the puzzle. As the
understanding of TRAF6 and its effectors continues to be understood, the use and affinity
of TRAF6 inhibitors will prove to me more efficacious as our understanding improves.
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